Eximias


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA

Eximias is developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA

Company (Alive / Active)

Phone:

Fax:

Berwyn, 19312
Pennsylvania, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Eximias $0M Dec 4, 2018
Quintessence Biosciences $7.1M Oct 7, 2011
Horizon Therapeutics $63M Jul 10, 2009
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Eximias Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)